300 related articles for article (PubMed ID: 9465025)
1. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen.
Watanabe H; Pan ZQ; Schreiber-Agus N; DePinho RA; Hurwitz J; Xiong Y
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1392-7. PubMed ID: 9465025
[TBL] [Abstract][Full Text] [Related]
2. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.
Lee MH; Reynisdóttir I; Massagué J
Genes Dev; 1995 Mar; 9(6):639-49. PubMed ID: 7729683
[TBL] [Abstract][Full Text] [Related]
3. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
Matsuoka S; Edwards MC; Bai C; Parker S; Zhang P; Baldini A; Harper JW; Elledge SJ
Genes Dev; 1995 Mar; 9(6):650-62. PubMed ID: 7729684
[TBL] [Abstract][Full Text] [Related]
4. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1.
Luo Y; Hurwitz J; Massagué J
Nature; 1995 May; 375(6527):159-61. PubMed ID: 7753174
[TBL] [Abstract][Full Text] [Related]
5. The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain.
Joaquin M; Watson RJ
J Biol Chem; 2003 Nov; 278(45):44255-64. PubMed ID: 12947099
[TBL] [Abstract][Full Text] [Related]
6. New functional activities for the p21 family of CDK inhibitors.
LaBaer J; Garrett MD; Stevenson LF; Slingerland JM; Sandhu C; Chou HS; Fattaey A; Harlow E
Genes Dev; 1997 Apr; 11(7):847-62. PubMed ID: 9106657
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Shankland SJ; Eitner F; Hudkins KL; Goodpaster T; D'Agati V; Alpers CE
Kidney Int; 2000 Aug; 58(2):674-83. PubMed ID: 10916090
[TBL] [Abstract][Full Text] [Related]
8. Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression.
Hashimoto Y; Kohri K; Kaneko Y; Morisaki H; Kato T; Ikeda K; Nakanishi M
J Biol Chem; 1998 Jun; 273(26):16544-50. PubMed ID: 9632724
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
Orend G; Hunter T; Ruoslahti E
Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
Rousseau D; Cannella D; Boulaire J; Fitzgerald P; Fotedar A; Fotedar R
Oncogene; 1999 May; 18(21):3290-302. PubMed ID: 10359535
[TBL] [Abstract][Full Text] [Related]
11. Persistent and heterogenous expression of the cyclin-dependent kinase inhibitor, p27KIP1, in rat hearts during development.
Koh KN; Kang MJ; Frith-Terhune A; Park SK; Kim I; Lee CO; Koh GY
J Mol Cell Cardiol; 1998 Mar; 30(3):463-74. PubMed ID: 9515024
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
13. Involvement of p27KIP1 in the proliferation of the developing corneal endothelium.
Yoshida K; Kase S; Nakayama K; Nagahama H; Harada T; Ikeda H; Harada C; Imaki J; Ohgami K; Shiratori K; Ilieva IB; Ohno S; Nishi S; Nakayama KI
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2163-7. PubMed ID: 15223790
[TBL] [Abstract][Full Text] [Related]
14. The cyclin kinase inhibitor p57kip2 regulates TGF-beta-induced compensatory tubular hypertrophy: effect of the immunomodulator AS101.
Sinuani I; Weissgarten J; Beberashvili I; Rapoport MJ; Sandbank J; Feldman L; Albeck M; Averbukh Z; Sredni B
Nephrol Dial Transplant; 2009 Aug; 24(8):2328-38. PubMed ID: 19321762
[TBL] [Abstract][Full Text] [Related]
15. Cooperation between the Cdk inhibitors p27(KIP1) and p57(KIP2) in the control of tissue growth and development.
Zhang P; Wong C; DePinho RA; Harper JW; Elledge SJ
Genes Dev; 1998 Oct; 12(20):3162-7. PubMed ID: 9784491
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the Cip/Kip family.
Hengst L; Reed SI
Curr Top Microbiol Immunol; 1998; 227():25-41. PubMed ID: 9479824
[No Abstract] [Full Text] [Related]
17. Formation of p27-CDK complexes during the human mitotic cell cycle.
Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
[TBL] [Abstract][Full Text] [Related]
18. Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors.
Brooks G; Poolman RA; Li JM
Cardiovasc Res; 1998 Aug; 39(2):301-11. PubMed ID: 9798515
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
Rousseau D; Cannella D; Boulaire J; Fitzgerald P; Fotedar A; Fotedar R
Oncogene; 1999 Jul; 18(30):4313-25. PubMed ID: 10439039
[TBL] [Abstract][Full Text] [Related]
20. The cyclin-dependent kinase inhibitor p27(Kip1) induces N-terminal proteolytic cleavage of cyclin A.
Bastians H; Townsley FM; Ruderman JV
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15374-81. PubMed ID: 9860976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
